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M A N U S C R I P T A C C E P T E D INTRODUCTION

MYH9-related disease (MYH9-RD) is an autosomal-dominant disorder characterized by
thrombocytopenia, giant platelets and inclusion bodies in neutrophils deriving from the aggregation of mutant and wild type proteins [1] [2] [3] . In addition to the hematological features, patients can develop, during infancy or adult life, sensorineural hearing loss, presenile cataract and/or proteinuric nephropathy that often leads to end-stage renal disease [4, 5] .
MYH9-RD is caused by mutations of MYH9, the gene encoding for the heavy chain (myosin-9) of the isoform A of the non-muscle myosin of class II [6, 7] . Class II myosins are hexameric complexes consisting of two heavy chains and two pairs of light chains. Each heavy chain contains a N-terminal globular head or motor domain, a long alpha-helix coiled-coil tail domain, and a short C-terminal non-helical tailpiece. The spectrum of mutations identified in the MYH9 gene is limited, consisting of 44 different alterations, mainly amino acids substitutions, hitting only 35 of the 1960 residues of myosin-9. In fact, residues Ser96 or Arg702 of the globular head, and Arg1165, Asp1424, or Glu1841 of the coiled coil domain, or Arg1933 of the non-helical tailpiece are mutated in 79% of the reported families. The remaining alterations are private or detected in a few cases [2] .
Genotype/phenotype studies have been reported showing that individuals with mutations in the motor domain of myosin-9 have more severe thrombocytopenia and higher risk of developing nephropathy and deafness [8] [9] [10] . Conversely, mutations in the tail domain are associated with a milder phenotype characterized by slight to moderate thrombocytopenia and a lower prevalence of extra-haematological manifestations.
In this paper, we report the identification of five novel mutations, three missense variations in exons 1, 16, and 30, and two in frame alterations of exons 20 and 24, thus extending the spectrum of mutations associated with MYH9-RD. The patients from these pedigrees presented with phenotypes consistent with the results of previous genotype/phenotype studies.
PATIENTS AND METHODS
Patients
Family 1. The proband (II-1; Table 1 and Fig. 1 ) was an 11-year-old boy referred for diagnostic investigation of familial thrombocytopenia. Since his mother had reduced platelet count he previously received a diagnosis of Bernard-Soulier syndrome. His platelet count was 60 x10 9 /L without bleeding history. Examination of peripheral blood smears after conventional staining M A N U S C R I P T Flow cytometry showed normal expression of the glycoproteins Ib-IX-V, IIb-IIIa, and Ia-IIa on the platelet surface; in vitro aggregation studies were not performed because of the low platelet count.
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Screening for kidney function revealed relevant proteinuria (2.2 gr/24 hours) and normal serum creatinine, while ophthalmological evaluation returned normal results (Table 1) .
Family 3. The proband (I-2; Table 1 ) was a 33-year-old female referred for thrombocytopenia The search for kidney damage, hearing loss, and cataracts returned normal results.
Immunofluorescence studies
Immunofluorescence analysis for myosin-9 localization in neutrophils was performed on peripheral blood smears using the NMG2 mouse monoclonal antibody. Goat anti-mouse conjugated with Alexa Fluor 488 (Invitrogen, Milan, Italy) was used for secondary detection, as previously described [11] .
Mutational analysis of MYH9
Probands City, CA) as previously described [11, 12] .
Bioinformatics
The structure with the closest sequence homology with MYH9 was identified by a Blast search of the PDB database (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The query sequence was aligned to that of the template by the clustalx software. The model was built using the expasy Swiss-Model repository used in automated mode (http://swissmodel.expasy.org/repository/).
RESULTS AND DISCUSSION
In the probands, the diagnosis of MYH9-RD was suspected because of the finding of giant platelets and typical Döhle-like basophilic inclusions in neutrophils, which was associated with the extrahematological manifestations of the disease in some cases (Table 1 ). In members of families 1-3 and 5, the immunofluorescence analysis revealed typical myosin-9 aggregates in neutrophil M A N U S C R I P T
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granulocytes, thus confirming the diagnosis [3, 11] . In families 1 and 2, the staining pattern was characterized by numerous aggregates of small size (<0.5 µm) (Fig 2C) , suggesting a mutation affecting the motor domain of myosin-9 [2, 4] . In families 3 and 5, patients' neutrophils had one to four large (2-5 µm) inclusions, often together with other small aggregates, as typically observed in subjects with alterations of the tail domain [2] . The immuofluorescence analysis was not performed in the members of family 4.
Mutational screening revealed five novel heterozygous mutations (Table 1 ). In the proband of families 1 and 2, we identified the c.101T>G (p.Val34Gly) and the c.2104C>A (p.Arg702Ser) missense mutations of exons 1 and 16, respectively ( Fig. 1 and 2 ). In families 3 and 4 we detected two in frame alterations, the c.2539_2559dup (p.Met847_Glu853dup) in exon 20 and the c.3142_3162del (p.Lys1048_Glu1054del) in exon 24 (Fig. 3 ). In the last proband, the c.4338G>T (Fig. 1D) . The valine is in the interface and is buried from the solvent (exposed surface area of 1 Å 2 ). It is surrounded by other hydrophobic residues (Ile49, Val57, Val59, Leu61, Leu70 and Ile75).
The identified mutation is therefore likely to have a structural role and destabilize the protein fold.
The arginine at residue 702 is also a conserved amino acid, as previously reported for other two mutations hitting the same residue, p.Arg702Cys and p.Arg702His [2, 7] . This residue is exposed on the protein surface (exposed surface area of 122 Å 2 ). The side chain points towards the spatially M A N U S C R I P T
nearby Glu94 with which Arg702 can form a salt bridge (Fig. 2D) . Mutation of the residue in the shorter serine and cysteine or in the pH sensitive histidine could abolish this interaction and lead to destabilization of the structure. As arginine 702, even asparagine at residue 1447 of the coiled-coil tail is a conserved amino acid, which was previously found to be hit by mutations p.Asp1447His and p.Asp1447Val in a few MYH9-RD patients [11, 13] .
Regarding the two in frame mutations, it is interesting to note that other in frame alterations, two deletions (c.3164_3205del/p.Gly1055_Gln1068del and c.3195_3215del/p.Glu1066_Ala1072del) and one duplication (c.3195_3215dup/p.Glu1066_Ala1072dup) have previously been identified in exon 24 [14, 15] . Such rearrangements are likely to derive from unequal homologous recombination between non-allelic regions repetitive elements, as hypothesized for c.3164_3205del and c.3195_3215del/dup. Indeed, exon 24 is rich of repetitive elements, including two AGCTGGAG units that are likely to be responsible for c.3142_3162del (Fig. 3A) . Similarly, the duplicated stretch of 21 bp in exon 20 is flanked by the AGGAGGAGGAG repetitive sequence (Fig. 3B) .
Interestingly, all these rearrangements remove or add 7 or 14 residues of the α-coiled coil rod domain of the myosin, which consists of a 28 amino acid unit repeated 40 times [16] . This unit is subdivided itself in four heptad repeat motifs that are typical of the coiled-coil structure. More precisely, the p.Met847_Glu853dup and p.Lys1048_Glu1054 mutations hit the second and the eighth units and are likely to cause a significant dominant negative effect by interfering with the correct dimerization of myosin-9 and its assembly in filaments.
We and others have recently reported genotype-phenotype correlations in MYH9-RD [9, 17] .
Patients with mutations affecting the globular head domain of myosin-9 have lower platelet counts and higher prevalence and severity of extra-hematological manifestations than the subjects with mutations in the tail domain. Consistent with these studies, the patients from family 1 presented with moderate to severe thrombocytopenia associated with sensorineural hearing loss and/or bilateral cataracts in both the adult members. Similarly, the patient of family 2 presented with very low platelet count associated with early-onset, profound deafness and proteinuric nephropathy. In particular, these findings confirm the previous observation that the arginine 702 substitution invariably affects the hearing and kidney function since the juvenile age [8] [9] [10] . On the contrary, patients from families 3-5 had slight to moderate thrombocytopenia and no extra-hematological manifestations, with the exception of a very mild, clinically unnoticed sensorineural hearing defect in the adult member of family 4.
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Despite the history of severe sensorineural deafness since the pediatric age, in the proband of family 2 the MYH9-RD was suspected only after the administration of several unnecessary treatments, including splenectomy, as a result of a wrong diagnosis of immune thrombocytopenia. As mentioned above, the mutation in this family is likely to have occurred as a de novo event, as both the patient's parents were healthy and had normal platelet counts. The lack of a familial history could have contributed to the misdiagnosis. Also the proband of family 3 received a wrong diagnosis of immune thrombocytopenia and undue treatments, despite her mother had a history of thrombocytopenia unresponsive to immunosuppressive drugs and splenectomy. These case reports emphasize the importance of considering the associated clinical manifestations typical of syndromic inherited thrombocytopenias, as well as of the examination of blood smears to search for giant platelets and Döhle-like leukocyte inclusions, in the evaluation of patients with thrombocytopenia [18] . Moreover, although in many cases the genetic origin of thrombocytopenia can be easily suspected for the presence of a low platelet count in one of the parents, it appears important the awareness that about 35% of MYH9-RD patients are sporadic cases, and, therefore, present with no familial history of thrombocytopenia [2] .
In conclusion, we reported five novel MYH9 mutations that extend the spectrum of alterations 
